{"transactions":[{"id":689681,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-08-12T20:43:49.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":1049283,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1049283},"source":{"system":"sec-edgar","filing":"0000947871-26-000784","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000784/ownership.xml","form_type":"4"}},{"id":689680,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-08-12T20:43:49.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":false,"shares":1039996,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1039996},"source":{"system":"sec-edgar","filing":"0000947871-26-000784","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000784/ownership.xml","form_type":"4"}},{"id":689679,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-12T20:43:49.000Z","date":"2026-08-10","kind":"purchase","planned":false,"acquired":true,"shares":625000,"price":16,"value":10000000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2714279,"source":{"system":"sec-edgar","filing":"0000947871-26-000784","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000784/ownership.xml","form_type":"4"}},{"id":689678,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-12T20:43:49.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":1049283,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2089279,"source":{"system":"sec-edgar","filing":"0000947871-26-000784","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000784/ownership.xml","form_type":"4"}},{"id":689677,"issuer":{"id":5423,"kind":"organization","name":"BlossomHill Therapeutics, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-12T20:43:49.000Z","date":"2026-08-10","kind":"exercise","planned":false,"acquired":true,"shares":1039996,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock (together, the \"Preferred Stock\") automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering on August 10, 2026 without payment of consideration. The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held directly by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1039996,"source":{"system":"sec-edgar","filing":"0000947871-26-000784","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000784/ownership.xml","form_type":"4"}},{"id":701620,"issuer":{"id":5494,"kind":"organization","name":"Scribe Therapeutics, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-07-29T22:47:29.000Z","date":"2026-07-27","kind":"exercise","planned":false,"acquired":false,"shares":2065672,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":348825},"source":{"system":"sec-edgar","filing":"0000947871-26-000733","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000733/ownership.xml","form_type":"4"}},{"id":701619,"issuer":{"id":5494,"kind":"organization","name":"Scribe Therapeutics, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-29T22:47:29.000Z","date":"2026-07-27","kind":"purchase","planned":false,"acquired":true,"shares":1000000,"price":15,"value":15000000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1348825,"source":{"system":"sec-edgar","filing":"0000947871-26-000733","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000733/ownership.xml","form_type":"4"}},{"id":701618,"issuer":{"id":5494,"kind":"organization","name":"Scribe Therapeutics, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-29T22:47:29.000Z","date":"2026-07-27","kind":"exercise","planned":false,"acquired":true,"shares":348825,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-0.1689 basis upon the closing of the Issuer's initial public offering on July 27, 2026 without payment of consideration. The Series B Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":348825,"source":{"system":"sec-edgar","filing":"0000947871-26-000733","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000733/ownership.xml","form_type":"4"}},{"id":712073,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-09T20:44:00.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":85918,"price":44.86,"value":3854281.48,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were sold pursuant to a 10b5-1 plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2469959,"source":{"system":"sec-edgar","filing":"0000947871-26-000694","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000694/ownership.xml","form_type":"4"}},{"id":719027,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T20:42:13.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":115844,"price":45.5,"value":5270902.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were sold pursuant to a 10b5-1 plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2555877,"source":{"system":"sec-edgar","filing":"0000947871-26-000683","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000683/ownership.xml","form_type":"4"}},{"id":759142,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-30T00:57:28.000Z","date":"2026-05-27","kind":"sale","planned":true,"acquired":false,"shares":101,"price":44.49,"value":4493.49,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were sold pursuant to a 10b5-1 plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2671721,"source":{"system":"sec-edgar","filing":"0000947871-26-000587","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000587/ownership.xml","form_type":"4"}},{"id":785331,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-11T22:58:53.000Z","date":"2026-05-11","kind":"sale","planned":true,"acquired":false,"shares":184639,"price":46.22,"value":8534014.58,"ownership":{"direct":false,"nature":"See footnotes("},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were sold pursuant to a 10b5-1 plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2671822,"source":{"system":"sec-edgar","filing":"0000947871-26-000517","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000517/ownership.xml","form_type":"4"}},{"id":785330,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-11T22:58:53.000Z","date":"2026-05-08","kind":"sale","planned":true,"acquired":false,"shares":59767,"price":44.58,"value":2664412.86,"ownership":{"direct":false,"nature":"See footnotes("},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were sold pursuant to a 10b5-1 plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2856461,"source":{"system":"sec-edgar","filing":"0000947871-26-000517","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000517/ownership.xml","form_type":"4"}},{"id":785329,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-11T22:58:53.000Z","date":"2026-05-07","kind":"sale","planned":true,"acquired":false,"shares":48546,"price":44.61,"value":2165637.06,"ownership":{"direct":false,"nature":"See footnotes("},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were sold pursuant to a 10b5-1 plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2916228,"source":{"system":"sec-edgar","filing":"0000947871-26-000517","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000517/ownership.xml","form_type":"4"}},{"id":799169,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Warrants (right to buy)","published_at":"2026-04-29T01:41:49.000Z","date":"2026-04-16","kind":"purchase","planned":false,"acquired":true,"shares":1793187,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 15, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain investors (the \"Investors\"), including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on April 16, 2026 (the \"Closing Date\") Series A warrants, Series B warrants, and Series C warrants (collectively, the \"Warrants\") to purchase up to an aggregate of 2,988,645 shares. The price per Pre-Funded Warrant is $1.673."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Warrants are exercisable pursuant to the conditions described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Warrants are exercisable pursuant to the conditions described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VIII. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1793187,"derivative":{"exercise_price":1.673,"underlying":"Common Stock","underlying_shares":1793187},"source":{"system":"sec-edgar","filing":"0000947871-26-000481","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000481/ownership.xml","form_type":"4"}},{"id":799168,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Warrants (right to buy)","published_at":"2026-04-29T01:41:49.000Z","date":"2026-04-16","kind":"purchase","planned":false,"acquired":true,"shares":597729,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 15, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain investors (the \"Investors\"), including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on April 16, 2026 (the \"Closing Date\") Series A warrants, Series B warrants, and Series C warrants (collectively, the \"Warrants\") to purchase up to an aggregate of 2,988,645 shares. The price per Pre-Funded Warrant is $1.673."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Warrants are exercisable pursuant to the conditions described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Warrants are exercisable pursuant to the conditions described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VIII. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":597729,"derivative":{"exercise_price":1.673,"underlying":"Common Stock","underlying_shares":597729},"source":{"system":"sec-edgar","filing":"0000947871-26-000481","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000481/ownership.xml","form_type":"4"}},{"id":799167,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants (right to buy)","published_at":"2026-04-29T01:41:49.000Z","date":"2026-04-16","kind":"purchase","planned":false,"acquired":true,"shares":597729,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 15, 2026, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain investors (the \"Investors\"), including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on April 16, 2026 (the \"Closing Date\") Series A warrants, Series B warrants, and Series C warrants (collectively, the \"Warrants\") to purchase up to an aggregate of 2,988,645 shares. The price per Pre-Funded Warrant is $1.673."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Warrants are exercisable pursuant to the conditions described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Warrants are exercisable pursuant to the conditions described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VIII. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":597729,"derivative":{"exercise_price":1.673,"underlying":"Common Stock","underlying_shares":597729},"source":{"system":"sec-edgar","filing":"0000947871-26-000481","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000481/ownership.xml","form_type":"4"}},{"id":799166,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-29T01:41:49.000Z","date":"2026-04-16","kind":"purchase","planned":false,"acquired":true,"shares":597729,"price":1.67,"value":998207.43,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VIII. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1203250,"source":{"system":"sec-edgar","filing":"0000947871-26-000481","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000481/ownership.xml","form_type":"4"}},{"id":803889,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T00:40:15.000Z","date":"2026-04-18","kind":"sale","planned":true,"acquired":false,"shares":2948,"price":44.52,"value":131244.96,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were sold pursuant to a 10b5-1 plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2964774,"source":{"system":"sec-edgar","filing":"0000947871-26-000458","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000458/ownership.xml","form_type":"4"}},{"id":803888,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T00:40:15.000Z","date":"2026-04-17","kind":"sale","planned":true,"acquired":false,"shares":52397,"price":44.68,"value":2341097.96,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were sold pursuant to a 10b5-1 plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2967722,"source":{"system":"sec-edgar","filing":"0000947871-26-000458","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000458/ownership.xml","form_type":"4"}},{"id":807522,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-16T23:03:39.000Z","date":"2026-04-16","kind":"sale","planned":true,"acquired":false,"shares":226906,"price":45.34,"value":10287918.04,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were sold pursuant to a 10b5-1 plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3020119,"source":{"system":"sec-edgar","filing":"0000947871-26-000446","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000446/ownership.xml","form_type":"4"}},{"id":807521,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-16T23:03:39.000Z","date":"2026-04-15","kind":"sale","planned":true,"acquired":false,"shares":235863,"price":44.64,"value":10528924.32,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were sold pursuant to a 10b5-1 plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3247025,"source":{"system":"sec-edgar","filing":"0000947871-26-000446","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000446/ownership.xml","form_type":"4"}},{"id":807520,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-16T23:03:39.000Z","date":"2026-04-14","kind":"sale","planned":true,"acquired":false,"shares":47814,"price":44.51,"value":2128201.14,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These securities were sold pursuant to a 10b5-1 plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3482888,"source":{"system":"sec-edgar","filing":"0000947871-26-000446","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000446/ownership.xml","form_type":"4"}},{"id":919966,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-05T00:39:05.000Z","date":"2026-02-03","kind":"sale","planned":true,"acquired":false,"shares":29063,"price":44.58,"value":1295628.54,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3530702,"source":{"system":"sec-edgar","filing":"0000947871-26-000088","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000088/ownership.xml","form_type":"4"}},{"id":919965,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-05T00:39:05.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":1890,"price":44.57,"value":84237.3,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3559765,"source":{"system":"sec-edgar","filing":"0000947871-26-000088","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000088/ownership.xml","form_type":"4"}},{"id":958714,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-30T01:44:14.000Z","date":"2025-12-24","kind":"sale","planned":true,"acquired":false,"shares":33356,"price":44.55,"value":1486009.8,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3561655,"source":{"system":"sec-edgar","filing":"0000947871-25-001096","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125001096/ownership.xml","form_type":"4"}},{"id":962396,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-20T00:29:13.000Z","date":"2025-12-19","kind":"sale","planned":true,"acquired":false,"shares":875,"price":44.49,"value":38928.75,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3595011,"source":{"system":"sec-edgar","filing":"0000947871-25-001088","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125001088/ownership.xml","form_type":"4"}},{"id":962395,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-20T00:29:13.000Z","date":"2025-12-18","kind":"sale","planned":true,"acquired":false,"shares":100,"price":44.49,"value":4449.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3595886,"source":{"system":"sec-edgar","filing":"0000947871-25-001088","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125001088/ownership.xml","form_type":"4"}},{"id":962394,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-20T00:29:13.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":900,"price":44.5,"value":40050.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3595986,"source":{"system":"sec-edgar","filing":"0000947871-25-001088","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125001088/ownership.xml","form_type":"4"}},{"id":987556,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-26T23:45:41.000Z","date":"2025-11-26","kind":"sale","planned":true,"acquired":false,"shares":1600,"price":44.49,"value":71184.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3596886,"source":{"system":"sec-edgar","filing":"0000947871-25-001045","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125001045/ownership.xml","form_type":"4"}},{"id":987555,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-26T23:45:41.000Z","date":"2025-11-25","kind":"sale","planned":true,"acquired":false,"shares":11890,"price":44.6,"value":530294.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3598486,"source":{"system":"sec-edgar","filing":"0000947871-25-001045","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125001045/ownership.xml","form_type":"4"}},{"id":987554,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-26T23:45:41.000Z","date":"2025-11-24","kind":"sale","planned":true,"acquired":false,"shares":94583,"price":44.54,"value":4212726.82,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3610376,"source":{"system":"sec-edgar","filing":"0000947871-25-001045","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125001045/ownership.xml","form_type":"4"}},{"id":1191362,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-26T23:00:01.000Z","date":"2025-03-24","kind":"sale","planned":false,"acquired":false,"shares":756,"price":54.11,"value":40907.16,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":186541,"source":{"system":"sec-edgar","filing":"0000947871-25-000345","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000345/ownership.xml","form_type":"4"}},{"id":1191361,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-26T23:00:01.000Z","date":"2025-03-24","kind":"sale","planned":false,"acquired":false,"shares":3026,"price":54.11,"value":163736.86,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":746171,"source":{"system":"sec-edgar","filing":"0000947871-25-000345","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000345/ownership.xml","form_type":"4"}},{"id":1191360,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-26T23:00:01.000Z","date":"2025-03-24","kind":"sale","planned":false,"acquired":false,"shares":1956,"price":54.11,"value":105839.16,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":482308,"source":{"system":"sec-edgar","filing":"0000947871-25-000345","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000345/ownership.xml","form_type":"4"}},{"id":1194971,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-22T00:00:03.000Z","date":"2025-03-21","kind":"sale","planned":false,"acquired":false,"shares":1320,"price":54,"value":71280.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":187297,"source":{"system":"sec-edgar","filing":"0000947871-25-000333","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000333/ownership.xml","form_type":"4"}},{"id":1194970,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-22T00:00:03.000Z","date":"2025-03-21","kind":"sale","planned":false,"acquired":false,"shares":5279,"price":54,"value":285066.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":749197,"source":{"system":"sec-edgar","filing":"0000947871-25-000333","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000333/ownership.xml","form_type":"4"}},{"id":1194969,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-22T00:00:03.000Z","date":"2025-03-21","kind":"sale","planned":false,"acquired":false,"shares":3412,"price":54,"value":184248.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":484264,"source":{"system":"sec-edgar","filing":"0000947871-25-000333","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000333/ownership.xml","form_type":"4"}},{"id":1194968,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-22T00:00:03.000Z","date":"2025-03-20","kind":"sale","planned":false,"acquired":false,"shares":364,"price":54.01,"value":19659.64,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":188617,"source":{"system":"sec-edgar","filing":"0000947871-25-000333","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000333/ownership.xml","form_type":"4"}},{"id":1194967,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-22T00:00:03.000Z","date":"2025-03-20","kind":"sale","planned":false,"acquired":false,"shares":1457,"price":54.01,"value":78692.57,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":754476,"source":{"system":"sec-edgar","filing":"0000947871-25-000333","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000333/ownership.xml","form_type":"4"}},{"id":1194966,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-22T00:00:03.000Z","date":"2025-03-20","kind":"sale","planned":false,"acquired":false,"shares":941,"price":54.01,"value":50823.41,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":487676,"source":{"system":"sec-edgar","filing":"0000947871-25-000333","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000333/ownership.xml","form_type":"4"}},{"id":1194965,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-22T00:00:03.000Z","date":"2025-03-19","kind":"sale","planned":false,"acquired":false,"shares":5228,"price":54.02,"value":282416.56,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":188981,"source":{"system":"sec-edgar","filing":"0000947871-25-000333","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000333/ownership.xml","form_type":"4"}},{"id":1194964,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-22T00:00:03.000Z","date":"2025-03-19","kind":"sale","planned":false,"acquired":false,"shares":20911,"price":54.02,"value":1129612.22,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":755933,"source":{"system":"sec-edgar","filing":"0000947871-25-000333","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000333/ownership.xml","form_type":"4"}},{"id":1194963,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-22T00:00:03.000Z","date":"2025-03-19","kind":"sale","planned":false,"acquired":false,"shares":13517,"price":54.02,"value":730188.34,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":488617,"source":{"system":"sec-edgar","filing":"0000947871-25-000333","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000333/ownership.xml","form_type":"4"}},{"id":1210588,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:34:10.000Z","date":"2025-03-12","kind":"sale","planned":false,"acquired":false,"shares":10733,"price":54.44,"value":584304.52,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $54.00 to a high of $54.96 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":194209,"source":{"system":"sec-edgar","filing":"0000947871-25-000308","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000308/ownership.xml","form_type":"4"}},{"id":1210587,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:34:10.000Z","date":"2025-03-12","kind":"sale","planned":false,"acquired":false,"shares":42930,"price":54.44,"value":2337109.2,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $54.00 to a high of $54.96 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":776844,"source":{"system":"sec-edgar","filing":"0000947871-25-000308","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000308/ownership.xml","form_type":"4"}},{"id":1210586,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:34:10.000Z","date":"2025-03-12","kind":"sale","planned":false,"acquired":false,"shares":27750,"price":54.44,"value":1510710.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $54.00 to a high of $54.96 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":502134,"source":{"system":"sec-edgar","filing":"0000947871-25-000308","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000308/ownership.xml","form_type":"4"}},{"id":1210585,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:34:10.000Z","date":"2025-03-12","kind":"sale","planned":false,"acquired":false,"shares":233,"price":55.05,"value":12826.65,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $55.03 to a high of $55.11 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":204942,"source":{"system":"sec-edgar","filing":"0000947871-25-000308","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000308/ownership.xml","form_type":"4"}},{"id":1210584,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:34:10.000Z","date":"2025-03-12","kind":"sale","planned":false,"acquired":false,"shares":933,"price":55.05,"value":51361.65,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $55.03 to a high of $55.11 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":819774,"source":{"system":"sec-edgar","filing":"0000947871-25-000308","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000308/ownership.xml","form_type":"4"}},{"id":1210583,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:34:10.000Z","date":"2025-03-12","kind":"sale","planned":false,"acquired":false,"shares":603,"price":55.05,"value":33195.15,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $55.03 to a high of $55.11 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":529884,"source":{"system":"sec-edgar","filing":"0000947871-25-000308","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000308/ownership.xml","form_type":"4"}},{"id":1210582,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:34:10.000Z","date":"2025-03-11","kind":"sale","planned":false,"acquired":false,"shares":3567,"price":54.01,"value":192653.67,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $54.00 to a high of $54.07 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":205175,"source":{"system":"sec-edgar","filing":"0000947871-25-000308","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000308/ownership.xml","form_type":"4"}},{"id":1210581,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:34:10.000Z","date":"2025-03-11","kind":"sale","planned":false,"acquired":false,"shares":14267,"price":54.01,"value":770560.67,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $54.00 to a high of $54.07 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":820707,"source":{"system":"sec-edgar","filing":"0000947871-25-000308","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000308/ownership.xml","form_type":"4"}},{"id":1210580,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:34:10.000Z","date":"2025-03-11","kind":"sale","planned":false,"acquired":false,"shares":9222,"price":54.01,"value":498080.22,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $54.00 to a high of $54.07 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":530487,"source":{"system":"sec-edgar","filing":"0000947871-25-000308","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000308/ownership.xml","form_type":"4"}},{"id":1210579,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:34:10.000Z","date":"2025-03-10","kind":"sale","planned":false,"acquired":false,"shares":53,"price":55.01,"value":2915.53,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $55.01 to a high of $55.02 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":208742,"source":{"system":"sec-edgar","filing":"0000947871-25-000308","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000308/ownership.xml","form_type":"4"}},{"id":1210578,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:34:10.000Z","date":"2025-03-10","kind":"sale","planned":false,"acquired":false,"shares":211,"price":55.01,"value":11607.11,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $55.01 to a high of $55.02 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":834974,"source":{"system":"sec-edgar","filing":"0000947871-25-000308","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000308/ownership.xml","form_type":"4"}},{"id":1210577,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:34:10.000Z","date":"2025-03-10","kind":"sale","planned":false,"acquired":false,"shares":136,"price":55.01,"value":7481.36,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $55.01 to a high of $55.02 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":539709,"source":{"system":"sec-edgar","filing":"0000947871-25-000308","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000308/ownership.xml","form_type":"4"}},{"id":1210576,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:34:10.000Z","date":"2025-03-10","kind":"sale","planned":false,"acquired":false,"shares":26596,"price":54.29,"value":1443896.84,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $54.00 to a high of $54.66 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":208795,"source":{"system":"sec-edgar","filing":"0000947871-25-000308","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000308/ownership.xml","form_type":"4"}},{"id":1210575,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:34:10.000Z","date":"2025-03-10","kind":"sale","planned":false,"acquired":false,"shares":106384,"price":54.29,"value":5775587.36,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $54.00 to a high of $54.66 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":835185,"source":{"system":"sec-edgar","filing":"0000947871-25-000308","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000308/ownership.xml","form_type":"4"}},{"id":1210574,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-13T01:34:10.000Z","date":"2025-03-10","kind":"sale","planned":false,"acquired":false,"shares":68766,"price":54.29,"value":3733306.14,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price of the shares of the Issuer's common stock purchased, ranging from a low of $54.00 to a high of $54.66 per share. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":539845,"source":{"system":"sec-edgar","filing":"0000947871-25-000308","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000308/ownership.xml","form_type":"4"}},{"id":1277135,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C convertible preferred stock","published_at":"2025-02-10T21:28:39.000Z","date":"2025-02-10","kind":"exercise","planned":false,"acquired":false,"shares":2048760,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1402204},"source":{"system":"sec-edgar","filing":"0000947871-25-000120","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000120/ownership.xml","form_type":"4"}},{"id":1277134,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B convertible preferred stock","published_at":"2025-02-10T21:28:39.000Z","date":"2025-02-10","kind":"exercise","planned":false,"acquired":false,"shares":2560951,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1752755},"source":{"system":"sec-edgar","filing":"0000947871-25-000120","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000120/ownership.xml","form_type":"4"}},{"id":1277133,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-10T21:28:39.000Z","date":"2025-02-10","kind":"purchase","planned":false,"acquired":true,"shares":550000,"price":18,"value":9900000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3704959,"source":{"system":"sec-edgar","filing":"0000947871-25-000120","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000120/ownership.xml","form_type":"4"}},{"id":1277132,"issuer":{"id":5996,"kind":"organization","name":"Sionna Therapeutics, Inc.","symbol":"SION"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-10T21:28:39.000Z","date":"2025-02-10","kind":"exercise","planned":false,"acquired":true,"shares":3154959,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B convertible preferred stock and Series C convertible preferred stock (collectively, the \"Preferred Stock\") automatically converted into shares of the Issuer's Common Stock on a one-for-1.4611 basis upon the closing of the Issuer's initial public offering on February 10, 2025. The Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors LLC (\"Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VIII and as a result may be deemed to have beneficial ownership of such shares. Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Peter A. Thompson, a member of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3154959,"source":{"system":"sec-edgar","filing":"0000947871-25-000120","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000120/ownership.xml","form_type":"4"}},{"id":1294715,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrant (right to buy)","published_at":"2025-01-28T00:03:50.000Z","date":"2024-12-29","kind":"purchase","planned":false,"acquired":true,"shares":96348,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Series A Warrants shall become exercisable on June 30, 2025; provided however, that the Series A Warrants may not be exercised prior to the issuer's receipt of stockholder approval of the exercise of the Series A Warrants, in accordance with Nasdaq listing rules."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Series A Warrants shall expire on the date that is the earlier of (a) December 31, 2029, and (b) subject to the fulfilment of certain equity conditions, thirty trading days after the last of the following data readouts to occur, as announced by the issuer: (i) Ferret animal model Bird Flu data, (ii) non-human primate Bird Flu data, or (iii) Phase 2a Influenza A human clinical data."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including any of the reporting persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":96348,"derivative":{"exercise_price":13.42,"underlying":"Common Stock","underlying_shares":96348},"source":{"system":"sec-edgar","filing":"0001104659-25-006409","document":"tm254427-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000110465925006409/tm254427-4_4seq1.xml","form_type":"4"}},{"id":1294714,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant (right to buy)","published_at":"2025-01-28T00:03:50.000Z","date":"2024-12-29","kind":"purchase","planned":false,"acquired":true,"shares":96348,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Pre-Funded Warrants shall become exercisable upon stockholder approval of the exercise of the Pre-Funded Warrants, in accordance with Nasdaq listing rules."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants do not expire."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of OrbiMed Advisors and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such person or entity, including any of the reporting persons, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":96348,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":96348},"source":{"system":"sec-edgar","filing":"0001104659-25-006409","document":"tm254427-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000110465925006409/tm254427-4_4seq1.xml","form_type":"4"}},{"id":1375916,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Simple Agreement for Future Equity","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":false,"shares":74613,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"These shares are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\") issued upon the conversion of an outstanding SAFE in the amount of $268,606.84, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors is the managing member of GP IX. By virtue of such relationships, OrbiMed Advisors and GP IX may be deemed to have voting and investment power over the securities held by OPI IX and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F6","text":"These shares are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\") issued upon the conversion of an outstanding SAFE in the amount of $268,606.84, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors is the managing member of GP IX. By virtue of such relationships, OrbiMed Advisors and GP IX may be deemed to have voting and investment power over the securities held by OPI IX and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These shares are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\") issued upon the conversion of an outstanding SAFE in the amount of $268,606.84, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors is the managing member of GP IX. By virtue of such relationships, OrbiMed Advisors and GP IX may be deemed to have voting and investment power over the securities held by OPI IX and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"These shares are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\") issued upon the conversion of an outstanding SAFE in the amount of $268,606.84, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors is the managing member of GP IX. By virtue of such relationships, OrbiMed Advisors and GP IX may be deemed to have voting and investment power over the securities held by OPI IX and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These shares are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\") issued upon the conversion of an outstanding SAFE in the amount of $268,606.84, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors is the managing member of GP IX. By virtue of such relationships, OrbiMed Advisors and GP IX may be deemed to have voting and investment power over the securities held by OPI IX and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":74613},"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375915,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Simple Agreement for Future Equity","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":false,"shares":230753,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"These shares are held of record by OPI VIII issued upon the conversion of an outstanding SAFE in the amount of $830,712.12, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F5","text":"These shares are held of record by OPI VIII issued upon the conversion of an outstanding SAFE in the amount of $830,712.12, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These shares are held of record by OPI VIII issued upon the conversion of an outstanding SAFE in the amount of $830,712.12, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"These shares are held of record by OPI VIII issued upon the conversion of an outstanding SAFE in the amount of $830,712.12, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held of record by OPI VIII issued upon the conversion of an outstanding SAFE in the amount of $830,712.12, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":230753},"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375914,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Simple Agreement for Future Equity","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":false,"shares":389078,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"These shares are held of record by OPI VII issued upon the conversion of an outstanding SAFE in the amount $1,400,681.04, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F4","text":"These shares are held of record by OPI VII issued upon the conversion of an outstanding SAFE in the amount $1,400,681.04, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These shares are held of record by OPI VII issued upon the conversion of an outstanding SAFE in the amount $1,400,681.04, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"These shares are held of record by OPI VII issued upon the conversion of an outstanding SAFE in the amount $1,400,681.04, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held of record by OPI VII issued upon the conversion of an outstanding SAFE in the amount $1,400,681.04, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":389078},"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375913,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Simple Agreement for Future Equity","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":false,"shares":215146,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"These shares are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\") issued upon the conversion of a SAFE in the amount of $688,465.75, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"These shares are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\") issued upon the conversion of a SAFE in the amount of $688,465.75, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These shares are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\") issued upon the conversion of a SAFE in the amount of $688,465.75, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These shares are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\") issued upon the conversion of a SAFE in the amount of $688,465.75, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\") issued upon the conversion of a SAFE in the amount of $688,465.75, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":215146},"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375912,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Simple Agreement for Future Equity","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":false,"shares":323916,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"These shares are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\") issued upon the conversion of an outstanding simple agreement for future equity (\"SAFE\") in the amount of $1,036,534.25, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."},{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\") issued upon the conversion of an outstanding simple agreement for future equity (\"SAFE\") in the amount of $1,036,534.25, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These shares are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\") issued upon the conversion of an outstanding simple agreement for future equity (\"SAFE\") in the amount of $1,036,534.25, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These shares are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\") issued upon the conversion of an outstanding simple agreement for future equity (\"SAFE\") in the amount of $1,036,534.25, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\") issued upon the conversion of an outstanding simple agreement for future equity (\"SAFE\") in the amount of $1,036,534.25, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":323916},"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375911,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"grant","planned":false,"acquired":true,"shares":155120,"price":4,"value":620480.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F9","text":"These shares are held of record by OPI IX issued upon the closing of the Offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These shares are held of record by OPI IX issued upon the closing of the Offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2677256,"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375910,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"grant","planned":false,"acquired":true,"shares":479736,"price":4,"value":1918944.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F8","text":"These shares are held of record by OPI VIII issued upon the closing of the Offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These shares are held of record by OPI VIII issued upon the closing of the Offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2522136,"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375909,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"grant","planned":false,"acquired":true,"shares":808894,"price":4,"value":3235576.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F7","text":"These shares are held of record by OPI VII issued upon the closing of the Offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These shares are held of record by OPI VII issued upon the closing of the Offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2042400,"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375908,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":true,"shares":74613,"price":3.6,"value":268606.8,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F6","text":"These shares are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\") issued upon the conversion of an outstanding SAFE in the amount of $268,606.84, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors is the managing member of GP IX. By virtue of such relationships, OrbiMed Advisors and GP IX may be deemed to have voting and investment power over the securities held by OPI IX and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These shares are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\") issued upon the conversion of an outstanding SAFE in the amount of $268,606.84, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors is the managing member of GP IX. By virtue of such relationships, OrbiMed Advisors and GP IX may be deemed to have voting and investment power over the securities held by OPI IX and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1233506,"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375907,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":true,"shares":230753,"price":3.6,"value":830710.8,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F5","text":"These shares are held of record by OPI VIII issued upon the conversion of an outstanding SAFE in the amount of $830,712.12, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These shares are held of record by OPI VIII issued upon the conversion of an outstanding SAFE in the amount of $830,712.12, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1158893,"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375906,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":true,"shares":389078,"price":3.6,"value":1400680.8,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F4","text":"These shares are held of record by OPI VII issued upon the conversion of an outstanding SAFE in the amount $1,400,681.04, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held of record by OPI VII issued upon the conversion of an outstanding SAFE in the amount $1,400,681.04, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":928140,"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375905,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":true,"shares":215146,"price":3.2,"value":688467.2,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"These shares are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\") issued upon the conversion of a SAFE in the amount of $688,465.75, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\") issued upon the conversion of a SAFE in the amount of $688,465.75, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII. OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":539062,"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1375904,"issuer":{"id":86303,"kind":"organization","name":"Lomond Therapeutics Holdings, Inc.","symbol":"NONE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":4,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-05T23:02:16.000Z","date":"2024-11-01","kind":"exercise","planned":false,"acquired":true,"shares":323916,"price":3.2,"value":1036531.2,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the \"Parent\"), Lomond Acquisition Corp., a Delaware corporation (the \"Acquisition Subsidiary\"), and Lomond Therapeutics, Inc. (\"Legacy Lomond\") (the \"Merger\"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the \"Merger\"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the \"Offering\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\") issued upon the conversion of an outstanding simple agreement for future equity (\"SAFE\") in the amount of $1,036,534.25, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\") issued upon the conversion of an outstanding simple agreement for future equity (\"SAFE\") in the amount of $1,036,534.25, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date. OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VII, GP VIII, and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":323916,"source":{"system":"sec-edgar","filing":"0001213900-24-094666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000121390024094666/ownership.xml","form_type":"4"}},{"id":1385168,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":3,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":4,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B redeemable convertible preferred stock","published_at":"2024-10-17T20:17:52.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":789833,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VIII. Advisors II, and Israel GP have designated a representative, Chimovits, an employee of OrbiMed Advisors and a director of Advisors II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":789833},"source":{"system":"sec-edgar","filing":"0000947871-24-000806","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000806/ownership.xml","form_type":"4"}},{"id":1385167,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":3,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":4,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B redeemable convertible preferred stock","published_at":"2024-10-17T20:17:52.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":197456,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"Advisors II\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors II may be deemed to have voting and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. Advisors II exercises voting and investment power through an investment committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits (\"Chimovits\"), each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VIII. Advisors II, and Israel GP have designated a representative, Chimovits, an employee of OrbiMed Advisors and a director of Advisors II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":197456},"source":{"system":"sec-edgar","filing":"0000947871-24-000806","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000806/ownership.xml","form_type":"4"}},{"id":1385166,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":3,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":4,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A redeemable convertible preferred stock","published_at":"2024-10-17T20:17:52.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":2098000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VIII. Advisors II, and Israel GP have designated a representative, Chimovits, an employee of OrbiMed Advisors and a director of Advisors II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2098000},"source":{"system":"sec-edgar","filing":"0000947871-24-000806","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000806/ownership.xml","form_type":"4"}},{"id":1385165,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":3,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":4,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A redeemable convertible preferred stock","published_at":"2024-10-17T20:17:52.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":false,"shares":524500,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"Advisors II\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors II may be deemed to have voting and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. Advisors II exercises voting and investment power through an investment committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits (\"Chimovits\"), each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VIII. Advisors II, and Israel GP have designated a representative, Chimovits, an employee of OrbiMed Advisors and a director of Advisors II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":524500},"source":{"system":"sec-edgar","filing":"0000947871-24-000806","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000806/ownership.xml","form_type":"4"}},{"id":1385164,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":3,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":4,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T20:17:52.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":660000,"price":17,"value":11220000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VIII. Advisors II, and Israel GP have designated a representative, Chimovits, an employee of OrbiMed Advisors and a director of Advisors II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":4554873,"source":{"system":"sec-edgar","filing":"0000947871-24-000806","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000806/ownership.xml","form_type":"4"}},{"id":1385163,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":3,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":4,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T20:17:52.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":2887833,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VIII. Advisors II, and Israel GP have designated a representative, Chimovits, an employee of OrbiMed Advisors and a director of Advisors II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3894873,"source":{"system":"sec-edgar","filing":"0000947871-24-000806","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000806/ownership.xml","form_type":"4"}},{"id":1385162,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":3,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":4,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T20:17:52.000Z","date":"2024-10-15","kind":"purchase","planned":false,"acquired":true,"shares":165000,"price":17,"value":2805000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"Advisors II\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors II may be deemed to have voting and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. Advisors II exercises voting and investment power through an investment committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits (\"Chimovits\"), each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VIII. Advisors II, and Israel GP have designated a representative, Chimovits, an employee of OrbiMed Advisors and a director of Advisors II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1138716,"source":{"system":"sec-edgar","filing":"0000947871-24-000806","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000806/ownership.xml","form_type":"4"}},{"id":1385161,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53131,"kind":"organization","name":"OrbiMed Advisors Israel II Ltd","position":3,"cik":"0001682093","reported_name":"OrbiMed Advisors Israel II Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":53132,"kind":"organization","name":"OrbiMed Israel GP II, L.P.","position":4,"cik":"0001682090","reported_name":"OrbiMed Israel GP II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T20:17:52.000Z","date":"2024-10-15","kind":"exercise","planned":false,"acquired":true,"shares":721956,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A redeemable convertible preferred stock and Series B redeemable convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-1.049 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Israel Partners II, L.P. (\"OIP II\"). OrbiMed Israel GP II, L.P. (\"Israel GP\") is the general partner of OIP II, and OrbiMed Advisors Israel II Limited (\"Advisors II\") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors II may be deemed to have voting and investment power over the securities held by OIP II and, as a result, may be deemed to have beneficial ownership over such securities. Advisors II exercises voting and investment power through an investment committee comprised of Carl L. Gordon, David P. Bonita, and Erez Chimovits (\"Chimovits\"), each of whom disclaims beneficial ownership of the securities held by OIP II."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Each of Advisors II, Israel GP, OrbiMed Advisors, and GP VIII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VIII. Advisors II, and Israel GP have designated a representative, Chimovits, an employee of OrbiMed Advisors and a director of Advisors II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":973716,"source":{"system":"sec-edgar","filing":"0000947871-24-000806","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000806/ownership.xml","form_type":"4"}},{"id":1473714,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-20T21:19:39.000Z","date":"2024-06-17","kind":"purchase","planned":false,"acquired":true,"shares":10986,"price":36,"value":395496.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis, and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VI, GP VIII, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":235391,"source":{"system":"sec-edgar","filing":"0000947871-24-000573","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000573/ownership.xml","form_type":"4"}},{"id":1473713,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-20T21:19:39.000Z","date":"2024-06-17","kind":"purchase","planned":false,"acquired":true,"shares":43944,"price":36,"value":1581984.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII, and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VI, GP VIII, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":941569,"source":{"system":"sec-edgar","filing":"0000947871-24-000573","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000573/ownership.xml","form_type":"4"}},{"id":1473712,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":51517,"kind":"person","name":"OrbiMed Capital GP VI LLC","position":2,"cik":"0001682115","reported_name":"OrbiMed Capital GP VI LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":4,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-20T21:19:39.000Z","date":"2024-06-17","kind":"purchase","planned":false,"acquired":true,"shares":28404,"price":36,"value":1022544.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These securities are held of record by OrbiMed Private Investments VI, LP (\"OPI VI\"). OrbiMed Capital GP VI LLC (\"GP VI\") is the general partner of OPI VI, and OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VI, GP VIII, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Mona Ashiya, an employee of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":608611,"source":{"system":"sec-edgar","filing":"0000947871-24-000573","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000573/ownership.xml","form_type":"4"}},{"id":1547118,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-05T20:33:30.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":450000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for (i) $2.5879 in cash per share (the \"Cash Amount\"), plus (ii) one non-transferable contingent value right (\"CVR\") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held of record by OrbiMed Partners Master Fund Limited (\"OPM\"). OrbiMed Capital LLC (\"OrbiMed Capital\") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-24-000353","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000353/ownership.xml","form_type":"4"}},{"id":1547117,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-05T20:33:30.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":84599,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for (i) $2.5879 in cash per share (the \"Cash Amount\"), plus (ii) one non-transferable contingent value right (\"CVR\") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"OrbiMed Genesis\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, OrbiMed Advisors and Genesis GP may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OrbiMed Genesis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-24-000353","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000353/ownership.xml","form_type":"4"}},{"id":1547116,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-05T20:33:30.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1368338,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for (i) $2.5879 in cash per share (the \"Cash Amount\"), plus (ii) one non-transferable contingent value right (\"CVR\") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Private Investments VIII, LP (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, OrbiMed Advisors and GP VIII may be deemed to have voting power and investment power over the securities held by OPI VIII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-24-000353","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000353/ownership.xml","form_type":"4"}},{"id":1547115,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-05T20:33:30.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4738453,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for (i) $2.5879 in cash per share (the \"Cash Amount\"), plus (ii) one non-transferable contingent value right (\"CVR\") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VII, LP (\"OPI VII\"). OrbiMed Capital GP VII LLC (\"GP VII\") is the general partner of OPI VII and OrbiMed Advisors is the managing member of GP VII. By virtue of such relationships, OrbiMed Advisors and GP VII may be deemed to have voting power and investment power over the securities held by OPI VII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-24-000353","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000353/ownership.xml","form_type":"4"}},{"id":1547114,"issuer":{"id":92187,"kind":"organization","name":"Kinnate Biopharma Inc.","symbol":"KNTE"},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35791,"kind":"organization","name":"OrbiMed Capital GP VII LLC","position":2,"cik":"0001760648","reported_name":"OrbiMed Capital GP VII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":3,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":5,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":6,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51518,"kind":"person","name":"ORBIMED CAPITAL LLC","position":7,"cik":"0001157524","reported_name":"ORBIMED CAPITAL LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-05T20:33:30.000Z","date":"2024-04-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1368339,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the \"Merger Agreement\") in exchange for (i) $2.5879 in cash per share (the \"Cash Amount\"), plus (ii) one non-transferable contingent value right (\"CVR\") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Asia Partners IV, L.P. (\"OAP IV\"). OrbiMed Asia GP IV, L.P. (\"Asia GP\") is the general partner of OAP IV and OrbiMed Advisors IV Limited (\"Advisors IV\") is the general partner of Asia GP. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the advisory company of OAP IV. By virtue of such relationships, Asia GP, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the securities held by OAP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Each of OrbiMed Advisors, Advisors IV, GP VIII, Asia GP, GP VII, OrbiMed Genesis, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors, GP VII, and GP VIII have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000947871-24-000353","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787124000353/ownership.xml","form_type":"4"}},{"id":1665594,"issuer":{"id":4699,"kind":"organization","name":"ArriVent BioPharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":3,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-01-31T21:12:19.000Z","date":"2024-01-30","kind":"exercise","planned":false,"acquired":false,"shares":469615,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, L.P. (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":469615},"source":{"system":"sec-edgar","filing":"0001104659-24-008799","document":"tm244611-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000110465924008799/tm244611-1_4seq1.xml","form_type":"4"}},{"id":1665593,"issuer":{"id":4699,"kind":"organization","name":"ArriVent BioPharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":3,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2024-01-31T21:12:19.000Z","date":"2024-01-30","kind":"exercise","planned":false,"acquired":false,"shares":469615,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Asia Partners IV, L.P. (\"OAP IV\"). OrbiMed Asia GP IV, L.P. (\"Asia GP IV\") is the general partner of OAP IV and OrbiMed Advisors IV Limited (\"Advisors IV\") is the general partner of Asia GP IV. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the advisory company of OAP IV. By virtue of such relationships, Asia GP IV, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OAP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":469615},"source":{"system":"sec-edgar","filing":"0001104659-24-008799","document":"tm244611-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000110465924008799/tm244611-1_4seq1.xml","form_type":"4"}},{"id":1665592,"issuer":{"id":4699,"kind":"organization","name":"ArriVent BioPharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":3,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2024-01-31T21:12:19.000Z","date":"2024-01-30","kind":"exercise","planned":false,"acquired":false,"shares":821827,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, L.P. (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":821827},"source":{"system":"sec-edgar","filing":"0001104659-24-008799","document":"tm244611-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000110465924008799/tm244611-1_4seq1.xml","form_type":"4"}},{"id":1665591,"issuer":{"id":4699,"kind":"organization","name":"ArriVent BioPharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":3,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2024-01-31T21:12:19.000Z","date":"2024-01-30","kind":"exercise","planned":false,"acquired":false,"shares":821827,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of preferred stock automatically converted into common stock immediately upon completion of the Issuer's initial public offering on a 15.21-for-1 basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares of preferred stock were convertible into the Issuer's common stock in accordance with the Issuer's Restated Certificate of Incorporation, as amended, immediately upon completion of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Asia Partners IV, L.P. (\"OAP IV\"). OrbiMed Asia GP IV, L.P. (\"Asia GP IV\") is the general partner of OAP IV and OrbiMed Advisors IV Limited (\"Advisors IV\") is the general partner of Asia GP IV. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the advisory company of OAP IV. By virtue of such relationships, Asia GP IV, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OAP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":821827},"source":{"system":"sec-edgar","filing":"0001104659-24-008799","document":"tm244611-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000110465924008799/tm244611-1_4seq1.xml","form_type":"4"}},{"id":1665590,"issuer":{"id":4699,"kind":"organization","name":"ArriVent BioPharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":3,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-31T21:12:19.000Z","date":"2024-01-30","kind":"purchase","planned":false,"acquired":true,"shares":222222,"price":18,"value":3999996.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Reflects shares purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments VIII, L.P. (\"OPI VIII\"). OrbiMed Capital GP VIII LLC (\"GP VIII\") is the general partner of OPI VIII and OrbiMed Advisors is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VIII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1513664,"source":{"system":"sec-edgar","filing":"0001104659-24-008799","document":"tm244611-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000110465924008799/tm244611-1_4seq1.xml","form_type":"4"}},{"id":1665589,"issuer":{"id":4699,"kind":"organization","name":"ArriVent BioPharma, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24291,"kind":"person","name":"OrbiMed Capital GP VIII LLC","position":2,"cik":"0001845804","reported_name":"OrbiMed Capital GP VIII LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92206,"kind":"person","name":"OrbiMed Advisors IV Ltd","position":3,"cik":"0001966835","reported_name":"OrbiMed Advisors IV Ltd","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":92205,"kind":"person","name":"OrbiMed Asia GP IV, L.P.","position":4,"cik":"0001966836","reported_name":"OrbiMed Asia GP IV, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-31T21:12:19.000Z","date":"2024-01-30","kind":"purchase","planned":false,"acquired":true,"shares":222222,"price":18,"value":3999996.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Reflects shares purchased in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are held of record by OrbiMed Asia Partners IV, L.P. (\"OAP IV\"). OrbiMed Asia GP IV, L.P. (\"Asia GP IV\") is the general partner of OAP IV and OrbiMed Advisors IV Limited (\"Advisors IV\") is the general partner of Asia GP IV. OrbiMed Advisors LLC (\"OrbiMed Advisors\") is the advisory company of OAP IV. By virtue of such relationships, Asia GP IV, Advisors IV, and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OAP IV and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OAP IV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP VIII, Advisors IV, and Asia GP IV. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1513664,"source":{"system":"sec-edgar","filing":"0001104659-24-008799","document":"tm244611-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000110465924008799/tm244611-1_4seq1.xml","form_type":"4"}}],"next_cursor":"2024-01-31T21:12:19.000000Z,1665589"}